Blood test flags effective breast cancer therapies before treatment starts
TL;DR
A London study shows a simple liquid biopsy measuring circulating tumour DNA (ctDNA) in advanced breast cancer can predict treatment response before starting therapy and after one cycle. In 167 patients, lower ctDNA levels were associated with better outcomes, suggesting this test could guide personalized treatment and spare ineffective drugs, with trials exploring adaptive strategies and newer therapies.
- Simple blood test can predict which breast cancer treatment will work best, study finds The Guardian
- ctDNA Positivity After Neoadjuvant T-DM1 May Predict HER2-Positive Breast Cancer Recurrence The ASCO Post
- Javier Pascual: ctDNA as a Key Predictor in Advanced Breast Cancer Oncodaily
- CtDNA Levels Post-Therapy Outshine PCR in Cancer Recurrence Mirage News
Want the full story? Read the original reporting
Read on The Guardian